UY31808A - Encapsulación de agentes biológicamente activos - Google Patents

Encapsulación de agentes biológicamente activos

Info

Publication number
UY31808A
UY31808A UY0001031808A UY31808A UY31808A UY 31808 A UY31808 A UY 31808A UY 0001031808 A UY0001031808 A UY 0001031808A UY 31808 A UY31808 A UY 31808A UY 31808 A UY31808 A UY 31808A
Authority
UY
Uruguay
Prior art keywords
biologically active
active agents
encapsulation
compositions
methods
Prior art date
Application number
UY0001031808A
Other languages
English (en)
Spanish (es)
Inventor
Papanicolaou Irene
Fidanboylu Mehmet
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40944671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31808(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of UY31808A publication Critical patent/UY31808A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UY0001031808A 2008-05-06 2009-05-05 Encapsulación de agentes biológicamente activos UY31808A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5077508P 2008-05-06 2008-05-06
US7417108P 2008-06-20 2008-06-20

Publications (1)

Publication Number Publication Date
UY31808A true UY31808A (es) 2009-12-14

Family

ID=40944671

Family Applications (4)

Application Number Title Priority Date Filing Date
UY0001031808A UY31808A (es) 2008-05-06 2009-05-05 Encapsulación de agentes biológicamente activos
UY0001031809A UY31809A (es) 2008-05-06 2009-05-05 Encapsulación de agentes biológicamente activos
UY0001031807A UY31807A (es) 2008-05-06 2009-05-05 Encapsulación de agentes biológicamente activos
UY0001031810A UY31810A (es) 2008-05-06 2009-05-05 Encapsulación de agentes biológicamente activos

Family Applications After (3)

Application Number Title Priority Date Filing Date
UY0001031809A UY31809A (es) 2008-05-06 2009-05-05 Encapsulación de agentes biológicamente activos
UY0001031807A UY31807A (es) 2008-05-06 2009-05-05 Encapsulación de agentes biológicamente activos
UY0001031810A UY31810A (es) 2008-05-06 2009-05-05 Encapsulación de agentes biológicamente activos

Country Status (11)

Country Link
US (1) US20110064821A1 (enExample)
EP (2) EP2271323A2 (enExample)
JP (1) JP2011522792A (enExample)
KR (3) KR20110010760A (enExample)
AR (4) AR072359A1 (enExample)
CA (1) CA2721241A1 (enExample)
CL (4) CL2009001076A1 (enExample)
PE (4) PE20091965A1 (enExample)
TW (4) TW201012489A (enExample)
UY (4) UY31808A (enExample)
WO (1) WO2009135853A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102088963A (zh) * 2008-05-06 2011-06-08 葛兰素集团有限公司 生物活性剂的囊封方法
WO2013021353A1 (en) 2011-08-11 2013-02-14 Bar-Ilan University Surface modified proteinaceous spherical particles and uses thereof
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
US10112987B2 (en) * 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
JP6612333B2 (ja) * 2014-05-30 2019-11-27 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 高薬物負荷ポリ（アルキル２−シアノアクリレート）ナノカプセル
JP6651507B2 (ja) * 2014-05-30 2020-02-19 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 抗原結合性分子のナノ封入
US20150359804A1 (en) * 2014-06-12 2015-12-17 Orbis Biosciences, Inc. Extended-release drug delivery compositions
JP6554493B2 (ja) 2014-06-24 2019-07-31 ザ・トラスティーズ・オブ・プリンストン・ユニバーシティＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｐｒｉｎｃｅｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 可溶性生物製剤、治療薬およびイメージング剤をカプセル化するためのプロセス
WO2019055539A1 (en) 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
JP2021501753A (ja) * 2017-11-03 2021-01-21 ザ・トラスティーズ・オブ・プリンストン・ユニバーシティＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｐｒｉｎｃｅｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 徐放性ナノキャリア製剤を形成するための疎水性イオン対化およびフラッシュナノ沈殿
US12186436B2 (en) 2018-07-19 2025-01-07 The Trustees Of Princeton University Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
US20220031630A1 (en) * 2018-09-13 2022-02-03 The Brigham And Women's Hospital, Inc. Nanoparticle formulations and methods of their use
US20200147032A1 (en) 2018-11-14 2020-05-14 Robert K. Prud'homme Dihydromyricetin hot melt extrusion formulations and methods for forming them

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833666A (en) 1986-12-24 1989-05-23 U.S. Philips Corporation Disc-record player suitable for scanning disc of different types
FR2649321A1 (fr) * 1989-07-07 1991-01-11 Inst Nat Sante Rech Med Compositions a base de derives nucleotidiques, leurs procedes de preparation, et leurs utilisations notamment en tant que compositions pharmaceutiques
FR2659554B1 (fr) * 1990-03-16 1994-09-30 Oreal Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant.
EP0683667A1 (en) * 1993-02-15 1995-11-29 Shield Research Limited Polyalkylcyanoacrylate nanocapsules
DE59409568D1 (de) * 1993-09-09 2000-11-30 Schering Ag Wirkstoffe und gas enthaltende mikropartikel
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20030152636A1 (en) * 2000-02-23 2003-08-14 Nanopharm Ag Method of treating cancer
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
AU2002354644C1 (en) * 2001-07-10 2009-04-30 Corixa Corporation Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
CA2531238C (en) 2003-07-04 2015-02-24 Affibody Ab Polypeptides having binding affinity for her2
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
KR20060129246A (ko) 2003-12-05 2006-12-15 컴파운드 쎄라퓨틱스, 인크. 타입 2 혈관 내피 성장 인자 수용체의 억제제
JP2008513363A (ja) 2004-09-14 2008-05-01 ナノデル テクノロジーズ ゲーエムベーハー ナノ粒子を含む送達媒体
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
PL2177536T3 (pl) 2006-03-30 2014-11-28 Glaxo Group Ltd Przeciwciała przeciwko peptydowi beta-amyloidu
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
BRPI0812398A2 (pt) 2007-06-06 2019-09-24 Domantis Ltd domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente à protease, uso do antagonista vegf, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão

Also Published As

Publication number Publication date
KR20110010758A (ko) 2011-02-07
PE20091964A1 (es) 2010-01-09
TW201006495A (en) 2010-02-16
CL2009001076A1 (es) 2010-09-24
CL2009001080A1 (es) 2010-09-24
TW201012489A (en) 2010-04-01
PE20091965A1 (es) 2010-01-09
KR20110015604A (ko) 2011-02-16
AR071634A1 (es) 2010-06-30
CA2721241A1 (en) 2009-11-12
UY31807A (es) 2009-12-14
AR072668A1 (es) 2010-09-15
PE20091882A1 (es) 2009-12-24
WO2009135853A2 (en) 2009-11-12
TW201012490A (en) 2010-04-01
TW201012488A (en) 2010-04-01
US20110064821A1 (en) 2011-03-17
JP2011522792A (ja) 2011-08-04
AR071633A1 (es) 2010-06-30
CL2009001077A1 (es) 2010-09-24
EP2441447A1 (en) 2012-04-18
AR072359A1 (es) 2010-08-25
EP2271323A2 (en) 2011-01-12
WO2009135853A3 (en) 2011-05-12
KR20110010760A (ko) 2011-02-07
UY31810A (es) 2009-12-14
PE20091829A1 (es) 2009-12-12
UY31809A (es) 2009-12-14
CL2009001081A1 (es) 2010-09-24

Similar Documents

Publication Publication Date Title
UY31809A (es) Encapsulación de agentes biológicamente activos
IN2014DN06529A (enExample)
NZ719345A (en) Lipid nanoparticle compositions and methods for mrna delivery
MX354137B (es) Composiciones topicas de minociclina y metodos de uso de la misma.
CO6571886A2 (es) Antagonistas de pcsk9
SG10201408166QA (en) Probiotic microorganisms as active agents for enhancing the radiance of the skin’s complexion
WO2013122932A3 (en) Topical use of a skin-commensal prebiotic agent and compositions containing the same
EA201190295A1 (ru) Композиции для дермальной доставки, содержащие комплексы активного агента с частицами фосфата кальция, и способы их применения
HK1206393A1 (en) Compositions and methods for diagnosis and treatment of pervasive developmental disorder
MX2019000547A (es) Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
CO6551683A2 (es) Tratamiento para trastornos gastrointestinales
MX2012009564A (es) ANTICUERPO NEUTRALIZANTE DE LA INTEGRINA AVß8.
IN2014DN08721A (enExample)
BRPI0912230A2 (pt) Método para encapsular agentes biologicamente ativos em um carreador particulado, carreador particulado, e, composição farmacêutica
CR20140594A (es) Composiciones farmacéuticas y tratamiento de mastitis
MX353207B (es) Encapsulacion de ingredientes en matriz de lactosa para formar encapsulados activos.
BR112013000779A2 (pt) composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial
CR20110550S (es) Botella
EP3087193A4 (en) Compositions and methods for providing active telomerase to cells in vivo
PL2753182T3 (pl) Środki czynne przeciw szczepom Pseudomonas powodującym choroby gnilne w uprawach grzybów, ich zastosowanie i zawierające je kompozycje
NI201100008A (es) Nuevas posibilidades de lucha contra la giardiasis.
IN2015DN04074A (enExample)
WO2009135854A3 (en) Encapsulation of biologically active agents
IN2014DN09812A (enExample)
WO2014031982A3 (en) Methods and compositions for treating pain